FINWIRES · TerminalLIVE
FINWIRES

Eli Lilly to Strengthen Cancer Treatment Portfolio With $7 Billion Deal for Kelonia

-- Eli Lilly (LLY) has agreed to acquire clinical-stage biotechnology firm Kelonia Therapeutics for up to $7 billion, as the drugmaker looks to bolster its cancer treatment portfolio.

The deal consideration consists of an upfront cash payment of $3.25 billion and subsequent payments upon the achievement of certain clinical, regulatory and commercial milestones, the companies said Monday.

The acquisition will give Lilly access to KLN-1010, Kelonia's lead investigational candidate for the treatment of multiple myeloma, a blood cancer of plasma cells in the bone marrow. The product is being evaluated in a phase 1 study.

"The early clinical data for KLN-1010 are highly encouraging, both as a potential step forward for patients with multiple myeloma and as proof of concept for Kelonia's platform," said Jacob Van Naarden, president of Lilly Oncology. "We look forward to working together with the Kelonia team to rapidly advance KLN-1010 to address patient need."

The deal, which requires approval from regulators, is expected to complete in the second half of this year.

"We have demonstrated the ability to achieve deep multiple myeloma remissions with significantly reduced complexity and cost relative to ex-vivo (chimeric antigen receptor) T-cell approaches," Kelonia Chief Executive Kevin Friedman said. "In combination with Lilly's strengths, our in-vivo (gene placement system) platform is positioned to broaden the reach of cell therapy beyond the current CAR-T landscape in hematologic malignancies."

Lilly shares edged 0.1% lower in Monday afternoon trade, taking its year-to-date losses to roughly 14%.

At the end of last month, Lilly announced an up to $7.8 billion deal to purchase UK-based Centessa Pharmaceuticals to strengthen its neuroscience pipeline and expand into sleep medicine. Earlier in the year, the company agreed to buy Orna Therapeutics, a biotechnology company focused on engineering immune cells, for up to $2.4 billion.

Lilly is scheduled to report first-quarter financial results April 30.

Price: $927.86, Change: $+0.83, Percent Change: +0.09%

Related Articles

Australia

Intel Poised for 'Slight Beat' Amid Solid Server CPU Demand, RBC Says

Intel (INTC) is expected to report a "slight beat" in its fiscal first-quarter results amid robust server central processing unit demand, RBC Capital Markets said in a note e-mailed Tuesday.On Thursday, the chipmaker is likely to post adjusted per-share earnings and revenue above RBC's projections for breakeven and $12.20 billion, respectively, for the March quarter, according to the brokerage. The current consensus on FactSet is for non-GAAP EPS of $0.02 and sales of $12.42 billion."We expect a slight beat/raise driven by strong server CPU demand," RBC analyst Srini Pajjuri said. "(Personal computer) market also appears to be holding up for now."First-quarter revenue in the company's data center and artificial intelligence segment is pegged at $4.3 billion, representing a 3% annual gain, with room for potential upside, according to RBC."While demand remains strong, management expected internal wafer supply constraints to be most acute in (the first quarter) which could limit near-term upside," Pajjuri wrote. "Recent media reports point to Intel raising prices which should help."For the current quarter, RBC expects Intel to issue an outlook above Wall Street's estimates of $13.1 billion in revenue and adjusted EPS of $0.09, driven by server CPU demand and improving wafer supply.The data center and AI business is projected to see sequential growth of 10% in the second quarter, with RBC seeing potential upside amid improving supply and healthy pricing. The brokerage expects server demand to continue to benefit from agentic AI and sees industry supply remaining "tight" through 2026, it said in the note.RBC maintained its sector perform rating on Intel's stock with a $48 price target.The company's shares were up 0.3% in Tuesday afternoon trade, bringing its year-to-gains to nearly 79%.Last year, the US government agreed to invest $8.9 billion in Intel's common stock as part of a deal to secure a stake in the company. Separately, Nvidia (NVDA) agreed to inject $5 billion in Intel under a collaboration that aims to develop new data center and PC chips.Price: $66.04, Change: $+0.34, Percent Change: +0.52%

$INTC$NVDA
Australia

Scholastic Reports Preliminary Results of Dutch Auction Tender Offer

Scholastic (SCHL) on Tuesday announced preliminary results from its modified Dutch auction tender offer, which closed on Monday.The company said that shareholders tendered a total of about 2.85 million shares at or below the $40 per share purchase price, including about 1 million shares that were tendered by notice of guaranteed delivery.Based on the preliminary count, Scholastic expects to purchase all properly tendered shares at $40 each, for a total cost of about $114.1 million, excluding fees and expenses, it added.The company said that following completion of the offer, it expects nearly 17.9 million shares to remain outstanding, representing a reduction of about 13.7% in its share count.Shares of Scholastic rose 2.3% in the session.Price: $40.69, Change: $+0.93, Percent Change: +2.34%

$SCHL
Sectors

Sector Update: Financial

Financial stocks were declining in Tuesday afternoon trading, with the NYSE Financial Index decreasing 0.7% and the State Street Financial Select Sector SPDR ETF (XLF) off 0.6%.The Philadelphia Housing Index was adding 0.6%, and the State Street Real Estate Select Sector SPDR ETF (XLRE) fell 1.8%.Bitcoin (BTC-USD) was decreasing 0.9% to $75,117, and the yield for 10-year US Treasuries was rising 5 basis points to 4.30%.In corporate news, Coinbase (COIN) and Gemini Titan have been sued by New York Attorney General Letitia James for allegedly violating the state laws against against illegal gambling with their prediction markets, Reuters reported, citing complaints filed in a state court in Manhattan. Coinbase shares fell nearly 7%.

$COIN